MX2016000294A - Composicion farmaceutica para liberacion sostenida de lanreotida. - Google Patents

Composicion farmaceutica para liberacion sostenida de lanreotida.

Info

Publication number
MX2016000294A
MX2016000294A MX2016000294A MX2016000294A MX2016000294A MX 2016000294 A MX2016000294 A MX 2016000294A MX 2016000294 A MX2016000294 A MX 2016000294A MX 2016000294 A MX2016000294 A MX 2016000294A MX 2016000294 A MX2016000294 A MX 2016000294A
Authority
MX
Mexico
Prior art keywords
lanreotide
sustained release
pharmaceutical composition
months
diseases
Prior art date
Application number
MX2016000294A
Other languages
English (en)
Other versions
MX367926B (es
Inventor
Roland Cherif-Cheikh
JOëL RICHARD
Ruth Bielsa Guivernau
Julie Fournes
Daniel Martinez Lorente
Anne Petit
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of MX2016000294A publication Critical patent/MX2016000294A/es
Publication of MX367926B publication Critical patent/MX367926B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue

Abstract

La presente invención se relaciona con una composición farmacéutica para una liberación sostenida de lanreótida, en particular para una liberación sostenida compatible con tratamientos terapéuticos por al menos 2 meses. Las composiciones farmacéuticas son particularmente útiles para el tratamiento de enfermedades, para las que la lanreótida está indicada.
MX2016000294A 2013-07-09 2014-07-08 Composicion farmaceutica para liberacion sostenida de lanreotida. MX367926B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13290156.2A EP2823808A1 (en) 2013-07-09 2013-07-09 Pharmaceutical composition for a sustained release of lanreotide
PCT/EP2014/064586 WO2015004125A1 (en) 2013-07-09 2014-07-08 Pharmaceutical composition for a sustained release of lanreotide

Publications (2)

Publication Number Publication Date
MX2016000294A true MX2016000294A (es) 2016-04-28
MX367926B MX367926B (es) 2019-09-12

Family

ID=48832841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000294A MX367926B (es) 2013-07-09 2014-07-08 Composicion farmaceutica para liberacion sostenida de lanreotida.

Country Status (20)

Country Link
US (1) US10543249B2 (es)
EP (2) EP2823808A1 (es)
JP (2) JP2016523945A (es)
KR (1) KR102232410B1 (es)
CN (1) CN105392470A (es)
AR (1) AR096854A1 (es)
AU (1) AU2014289332B2 (es)
CA (1) CA2917098A1 (es)
DK (1) DK3035912T3 (es)
EA (1) EA034224B1 (es)
ES (1) ES2928676T3 (es)
HU (1) HUE060497T2 (es)
IL (1) IL243027A0 (es)
MX (1) MX367926B (es)
PL (1) PL3035912T3 (es)
PT (1) PT3035912T (es)
SG (1) SG11201510698QA (es)
TW (1) TWI715520B (es)
UA (1) UA116569C2 (es)
WO (1) WO2015004125A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109381695A (zh) * 2017-08-09 2019-02-26 武汉武药科技有限公司 一种门冬氨酸帕瑞肽注射液及其制备方法和用途
FR3079421A1 (fr) 2018-03-28 2019-10-04 Edix Sa Presentations injectables, seringues et compositions a liberation prolongee et/ou controlee de lanreotide
ES2902784T3 (es) 2019-10-24 2022-03-29 Sun Pharmaceutical Ind Ltd Una forma de dosificación parenteral estable de acetato de Cetrorelix
GR1010059B (el) * 2020-08-10 2021-08-13 Φαρματεν Α.Β.Ε.Ε. Διαδικασια και συσκευη για την παρασκευη παχυρευστων φαρμακοτεχνικων μορφων
US20230277417A1 (en) 2020-08-07 2023-09-07 Pharmathen S.A. Process and apparatus for preparing viscous pharmaceutical formulations
LU101974B1 (en) 2020-08-07 2022-02-07 Pharmathen Sa Process and apparatus for preparing viscous pharmaceutical formulations
WO2023092148A1 (en) * 2021-11-22 2023-05-25 SpecGx LLC Injectable sustained release pharmaceutical composition

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US271189A (en) * 1883-01-23 beals
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
CN101590011A (zh) * 1994-09-02 2009-12-02 科学研究与运用咨询公司 肽从药物组合物中的持续释放
IL127769A (en) * 1996-07-03 2006-10-31 Alza Corp Non-aqueous protic preparations of peptides
FR2762319A1 (fr) 1997-04-18 1998-10-23 Pharma Biotech Microcapsules presentant une liberation prolongee et leur procede de preparation
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
IT1318539B1 (it) * 2000-05-26 2003-08-27 Italfarmaco Spa Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
US7098305B2 (en) 2001-09-06 2006-08-29 Ardana Bioscience Limited Sustained release of microcrystalline peptide suspensions
CN1415378A (zh) 2002-10-22 2003-05-07 南京长澳医药科技有限公司 生长抑素冻干粉针及其制备工艺
US20040247672A1 (en) 2003-05-16 2004-12-09 Alkermes Controlled Therapeutics, Inc. Injectable sustained release compositions
WO2006075124A1 (en) * 2005-01-14 2006-07-20 Camurus Ab Somatostatin analogue formulations
CN101022822B (zh) * 2004-08-24 2012-06-27 第一三共株式会社 生理学活性肽的液体制剂
WO2006065951A2 (en) * 2004-12-15 2006-06-22 Qlt Usa, Inc. Sustained delivery formulations of octreotide compounds
GB0428151D0 (en) * 2004-12-22 2005-01-26 Novartis Ag Organic compounds
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
GB0711656D0 (en) 2007-06-15 2007-07-25 Camurus Ab Formulations
FI120057B (fi) * 2007-07-13 2009-06-15 Andritz Oy Laite ja menetelmä lipeäruiskun puhdistamiseksi ja jäähdyttämiseksi
CA2710406A1 (en) 2007-09-11 2009-04-09 Dorian Bevec Use of a peptide as a therapeutic agent
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
WO2009095450A1 (en) * 2008-01-30 2009-08-06 Novartis Ag Sustained release formulation comprising octreotide and three linear polylactide-co-glycolide polymers
ES2600797T3 (es) 2008-08-12 2017-02-10 Novartis Ag Composiciones farmacéuticas
EP2168983A1 (fr) 2008-09-30 2010-03-31 Ipsen Pharma Nouveaux composés octapeptidiques et leur utilisation thérapeutique
AU2009336723B2 (en) * 2008-12-15 2013-06-06 Novartis Ag Nanoparticle compositions
US20120172650A1 (en) * 2009-03-18 2012-07-05 Laurence Katznelson Use of somatostatin or an analogue thereof in combination with external radiation therapy
US9352012B2 (en) * 2010-01-13 2016-05-31 Ipsen Pharma S.A.S. Process for the preparation of pharmaceutical compositions for the sustained release of somatostatin analogs
PE20141297A1 (es) * 2011-12-05 2014-10-09 Camurus Ab Formulaciones peptidicas robustas de liberacion controlada

Also Published As

Publication number Publication date
US10543249B2 (en) 2020-01-28
JP6811270B2 (ja) 2021-01-13
JP2019073564A (ja) 2019-05-16
CN105392470A (zh) 2016-03-09
IL243027A0 (en) 2016-02-29
EA201690191A1 (ru) 2016-06-30
WO2015004125A1 (en) 2015-01-15
EA034224B1 (ru) 2020-01-20
TW201536346A (zh) 2015-10-01
EP2823808A1 (en) 2015-01-14
EP3035912B1 (en) 2022-08-31
KR20160030232A (ko) 2016-03-16
DK3035912T3 (da) 2022-10-03
EP3035912A1 (en) 2016-06-29
JP2016523945A (ja) 2016-08-12
ES2928676T3 (es) 2022-11-21
HUE060497T2 (hu) 2023-03-28
US20160151447A1 (en) 2016-06-02
CA2917098A1 (en) 2015-01-15
PT3035912T (pt) 2022-10-26
AR096854A1 (es) 2016-02-03
SG11201510698QA (en) 2016-01-28
KR102232410B1 (ko) 2021-03-29
TWI715520B (zh) 2021-01-11
MX367926B (es) 2019-09-12
AU2014289332A1 (en) 2016-02-11
UA116569C2 (uk) 2018-04-10
PL3035912T3 (pl) 2022-12-05
AU2014289332B2 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
PE20150092A1 (es) Composiciones farmaceuticas que contienen fumarato de dimetilo
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
GB201209613D0 (en) New compounds
GB201118656D0 (en) New compounds
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
NZ749217A (en) Androgen receptor modulator and uses thereof
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201690107A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
MX2013008851A (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
MX349004B (es) Nuevos compuestos.
NZ727304A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
BR112012016853A2 (pt) "composições farmacêuticas para administração oral de peptídeos de insulina".
MX349224B (es) Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa.
EA201690187A1 (ru) Композиция в форме сухого порошка, содержащая кортикостероид и бета-адренергическое лекарственное средство, для введения ингаляцией
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.

Legal Events

Date Code Title Description
FG Grant or registration